1 
 
Comparative Analysis of Multi-Omics Integration 
Using Advanced Graph Neural Networks for Cancer 
Classification 
Fadi Alharbi 1, Aleksandar Vakanski 1, *, Boyu Zhang 1, Murtada K. Elbashir 2 and Mohanad Mohammed 3 
Affiliation: 1College of Engineering, Department of Computer Science, University of Idaho, Moscow, ID 
83844, USA; alha5622@vandals.uidaho.edu, vakanski@uidaho.com, boyuz@uidaho.edu 
2College of Computer and Information Sciences, Department of Information Systems, Jouf University, 
Sakaka, Aljouf 72441, Saudi Arabia; mkelfaki@ju.edu.sa  
3School 
of 
Mathematics, 
Statistics 
and 
Computer 
Science, 
University 
of 
KwaZulu-Natal, 
Pietermaritzburg, Scottsville, 3209, South Africa; mohanadadam32@gmail.com  
 
* Correspondence: vakanski@uidaho.com 
Abstract 
Multi-omics data is increasingly being utilized to advance computational methods for cancer 
classification. However, multi-omics data integration poses significant challenges due to the high 
dimensionality, data complexity, and distinct characteristics of various omics types. This study 
addresses these challenges and evaluates three graph neural network architectures for multi-omics 
(MO) integration based on graph-convolutional networks (GCN), graph-attention networks (GAT), 
and graph-transformer networks (GTN) for classifying 31 cancer types and normal tissues. To 
address the high-dimensionality of multi-omics data, we employed LASSO (Least Absolute 
Shrinkage and Selection Operator) regression for feature selection, leading to the creation of LASSO-
MOGCN, LASSO-MOGAT, and LASSO-MOTGN models. Graph structures for the networks were 
constructed using gene correlation matrices and protein-protein interaction networks for multi-
omics integration of messenger-RNA, micro-RNA, and DNA methylation data. Such data integration 
enables the networks to dynamically focus on important relationships between biological entities, 
improving both model performance and interpretability. Among the models, LASSO-MOGAT with a 
correlation-based graph structure achieved state-of-the-art accuracy (95.9%) and outperformed the 
LASSO-MOGCN and LASSO-MOTGN models in terms of precision, recall, and F1-score. Our findings 
demonstrate that integrating multi-omics data in graph-based architectures enhances cancer 
2 
 
classification performance by uncovering distinct molecular patterns that contribute to a better 
understanding of cancer biology and potential biomarkers for disease progression.  
Keywords: Gene expression analysis, graph neural networks, multi-omics data integration, cancer 
classification 
1. Introduction 
Gene expression is a fundamental cellular process that governs the translation of genetic 
information encoded in DNA into functional proteins, which in turn defines a cellâ€™s functionality and 
phenotype [1]. Recent advancements in gene expression analysis have significantly enhanced our 
understanding of the molecular pathology of various diseases, including cancer [2]. Particularly, the 
advent of high-throughput sequencing technologies has enabled genome-wide analysis of gene 
expression patterns, providing critical insights into tumorigenesis and cancer progression [3]. 
Moreover, the integration of gene expression data with other molecular datasets has proven effective 
for biomarker characterization, facilitating early cancer diagnostics and treatment methods 
selection [4]. By incorporating multiple layers of omics data, methods based on multi-omics data 
integration enable the identification of distinct molecular subtypes that might remain undetected 
with single-omics analyses. 
The analysis and interpretation of gene expression data have been facilitated by Machine Learning 
(ML)-based methods, due to the ability for pattern recognition in complex high-dimensional data. 
Consequently, ML models have been successfully applied to predict disease progression, 
differentiate cancer subtypes, and identify therapeutic targets with high levels of accuracy [5]. For 
instance, ML methods based on Random Forest, Support Vector Machines, and Neural Networks 
have been employed as feature selection tools to identify the most relevant genes within gene 
expression data for specific biological processes [6â€“8]. In addition, Deep Learning (DL) models have 
been essential in integrating multi-omics data by uncovering patterns and relationships within large, 
comprehensive datasets, thereby enabling the classification of clinically relevant subtypes to 
enhance prognosis and treatment effects [9]. DL-based approaches, in particular, have been 
extensively used to integrate gene expression data with other types of omics data, such as 
proteomics and metabolomics, to improve cancer prognosis through reductionist modeling [10].  
Graph Neural Networks (GNNs) have recently emerged as powerful tools for analyzing data with 
relational structures, such as biological networks, social networks, and knowledge graphs. GNNs 
3 
 
are designed to operate on data represented in the form of a graph, where nodes and edges model 
the relationships within the graph elements [11]. In the context of biological networks, GNNs have 
proven effective in capturing complex interactions between biological entities, e.g., in the form of 
protein-protein interaction networks and gene regulatory networks [12]. By representing these 
interactions as graphs, GNNs model the dependencies and hierarchical structures within biological 
systems, providing important insights into cellular processes. Recent emerging graph-based 
network architecture, such as Graph Convolutional Networks (GCNs), Graph Attention Networks 
(GATs), and Graph Transformer networks (GTNs), have further enhanced the performance of GNNs, 
enabling more accurate and interpretable outcomes [13]. GCNs extend the concept of convolution 
from traditional grid-based data, such as images, to graph structures, enabling the capture of 
information from a nodeâ€™s neighbors and creating a localized graph representation around a node 
[14]. This makes GCNs especially effective for tasks such as node classification and link prediction, 
where relationships between neighboring nodes are particularly important. GATs build on this 
concept by incorporating an attention mechanism, allowing the model to assign different weights to 
neighboring nodes for learning from complex graphs [15]. The attention mechanism enables GATs to 
concentrate on the important parts of the graph, improving performance on tasks involving 
heterogeneous graphs or graphs where certain connections are more significant. Graph Transformer 
Networks (GTNs) introduce transformer network architectures into graph learning, providing the 
ability to handle long-range geometric dependencies within the graph [16]. GTNs are particularly 
helpful for graph-level prediction tasks, as they focus on learning global features across the entire 
graph. Together, GCNs, GATs, and GTNs graph-based architectures contribute to advanced 
modeling of complex data structures enabling more accurate solutions across a range of tasks.  
This study provides an empirical evaluation of the performance of GCNs, GATs, and GTNs for 
classifying 31 types of cancers and normal tissues. In addition, the focus of the study is on evaluating 
the capacity for integrating multi-omics data, including different combinations of mRNA 
(messenger-RNA), miRNA (micro-RNA), and DNA methylation data. Our approach also applies 
LASSO (Least Absolute Shrinkage and Selection) regression for feature selection. Therefore, we 
dubbed the compared approaches LASSO-MOGCN (Multi-Omics Graph Convolutional Network), 
LASSO-MOGAT (Multi-Omics Graph Attention Network), and LASSO-MOGTN (Multi-Omics Graph 
Transformer Network). For modeling the relationships between the variables in these graph-based 
architectures, we used both gene correlation matrices and protein-protein interaction (PPI) 
networks to capture biological interaction and interdependence. The comparison reveals a notable 
4 
 
difference in the performance between single-omics data and multi-omics data, where the use of 
single omics data generally resulted in lower performance compared to the integration of more than 
one omics data type. For example, LASSO-MOGAT achieved an accuracy of 94.88% when it uses 
DNA methylation alone as input, 95.67% accuracy for integrating mRNA and DNA methylation, and 
95.90% accuracy based on the integration of mRNA, miRNA, and DNA methylation data. The 
improvement in the model performance highlights the importance of multi-omics integration in 
capturing biological signals by leveraging complementary information from different data types. 
Among the three approaches, LASSO-MOGAT architecture provides the best performance for both 
single-omics and multi-omics data.  
Unlike previous related works, this study compares three graph-based models using multi-omics 
data (mRNA, miRNA, DNA methylation) to classify 31 different types of cancer and normal tissues. 
While graph-based methods have recently been widely applied for cancer classification [17â€“21], few 
studies have focused on systematically comparing modern graph-based architectures and their 
performances across diverse omics data. For instance, Ramirez et al. [22] employed graph-
convolution networks (GCNs) for cancer classification using co-expressed genes and PPI networks. 
Nevertheless, their study did not investigate the performance of other graph architectures, such as 
GATs or GTNs. Schulte-Sasse et al. [23] introduced EMOGI, primarily targeting cancer gene 
prediction, but their work did not compare different GNN architectures for multi-omics integration. 
Different from prior works, our study presents a systematic comparison of GCNs, GATs, and GTNs 
for omics integration based on different graph structures.  Furthermore, unlike existing studies, we 
focus on feature selection with LASSO regression while using graph-based techniques for handling 
complex associations between multiple omics datasets. In a previous work by our team, we 
introduced a multi-omics GAT framework [24], which utilizes the PPI network as a graph structure . 
While our previous work focused on developing a GAT model for gene expression analysis, in the 
work presented in this paper, we evaluate three graph models, GCNs, GATs, and GTNs, based on 
both correlation matrices and PPI networks as graph structures.  
The key contributions of this study are as follows: 
â€¢ 
An empirical investigation of the performance of Graph Convolutional Networks (GCNs), 
Graph Attention Networks (GATs), and Graph Transformer networks (GTNs) based on 
integrating mRNA or RNA-Seq, miRNA, and DNA methylation data for classification of 31 
types of cancer and normal tissues.  
5 
 
â€¢ 
A comparative analysis between the performance of two graph structures based on 
correlation matrices and protein-protein interaction (PPI) networks.  
â€¢ 
The performance of LASSO-MOGAT utilizing correlation matrices demonstrated state-of-
the-art performance in comparison to existing neural network models using multi-omics 
data integration for cancer classification. 
2. Related Work 
In recent years, studies integrating multiple omics data sets have exhibited potential in moving 
forward cancer research by providing an improved understanding of the disease process. 
Computational models based on deep learning and attention-based architectures were applied to 
subtype cancer and enhanced model interpretability and identify biomarkers. However, challenges 
such as the modelsâ€™ applicability for other omics data, model interpretability, and clinical 
applicability, as well as challenges with regard to analyzing multiple omics data with high 
dimensions persist.  
Recently, Xiao et al. [25] introduced Multi-Prior Knowledge Graph Neural Network (MPKGNN) for 
cancer molecular subtype classification. The authors demonstrated that the incorporation of 
multiple Prior Knowledge Graphs in GNNs increases the volume of omics data that it is capable of 
classifying with high accuracy. Chatzianastasis et al. [26] developed Explainable Multilayer Graph 
Neural Network (EMGNN) for cancer gene prediction using gene interaction graphs and multi-omics 
data. This work identifies more than one interaction network for improved performance, however the 
ability for generalization to high dimensions and large-scale datasets remains unexplored.  
GCNs have also been used for cancer data analysis by integrating patient similarity networks with 
other omics data. For instance, Moon et al. [27] developed the Multi-Omics Module Analysis (MOMA) 
model, and Li et al. [28] introduced the Multi-omics Graph Convolutional Network (MoGCN). 
However, these works do not account for the various aspects of multiple omics data integration, 
especially the inter-omics associations essential in the classification of subtypes of cancer. 
Specifically, in MoGCN by Li et al. [28] GCNs are combined with autoencoders for feature learning, 
but Similarity Network Fusion formulates a significant portion of interactions across multiple omics 
layers which are important and can be neglected. 
Wang et al. [29] proposed Multi-Omics Graph Convolutional Networks (MOGONET), which includes 
a cross-omics correlation learning process. Although this study is more exhaustive, it also has 
6 
 
drawbacks regarding the model interpretability, as it is unclear how individual biomarkers are 
chosen for a particular disease. Likewise, Schulte-Sasse et al. [23] and Peng et al. [30] target 
enhancing biomarker discovery, however, the inability to clearly explain these models hampers their 
utility in precision medicine. This challenge has been mitigated by the use of attention mechanisms. 
Zhang et al. [31] and Guo et al. [32] applied attention-based GCNs for cancer classification with 
improved model explanations of cancer classification and patient biomarkers. Nevertheless, these 
models pose challenges in terms of scalability, generalizability, and robustness for complex multi-
omics datasets. The use of attention mechanisms may also lead to overfitting in a scenario where 
the number of samples used is significantly smaller compared to the number of features.  
Graph Transformer Networks (GTNs) are also promising architectures as they are capable of 
capturing long-range dependencies in complex biological data. Kaczmarek et al. [33] and Wang et 
al. [34] applied GTNs for cancer sample classification, combining multi-omics data with miRNA and 
mRNA sequencing data. Although these models offer better interpretability, especially in the 
identification of key biological pathways, they perform poorly in terms of accuracy compared to the 
traditional deep learning methods, thus a better combination of omis fusion techniques is required. 
There has also been extensive application of autoencoders for dimensionality reduction in multi-
omics data. Although the works by Zhang et al. [13] and Chai et al. [35] achieved high cancer 
classification accuracy, autoencoders are generally considered a black-box solution that lacks 
explanation, which can critically impact the utility of these algorithms. Additionally, due to the lack 
of ability to decode the intricate relations of different omics, autoencoders have shortcomings in 
comparison to feature learning with graph-based methods. 
The study by Khemani et al. [36] explores certain GNN models, such as graph attention networks 
(GATs), graph convolution networks (GCNs), and GraphSAGE that are currently widely employed in 
many different applications. Similarly, Lachi et al. [37] investigated scalable multi-graph pretraining. 
These studies addressed some of the prevalent challenges for generalizability and performance gain 
in graph learning. Although these works offer a comparison of advanced computational models, they 
fail to answer questions about the optimal level of balance between performance and interpretability 
in multi-omics data analysis.  Besides, research works aiming at solving problems on a larger scale, 
such as Zhao et al. [38] and Yang et al. [39], struggle with algorithmic issues of GNN models to 
process large and complex multi-omics data sets. These models also fail to learn long-range 
7 
 
dependencies in the data and between different omics features that are critical to comprehending 
tumor progression and therapeutic response.  
In conclusion, while efforts using graph-based architecture for cancer classification and biomarker 
identification have yielded promising results, several limitations remain. Prior approaches tend to 
prioritize performance or interpretability, nonetheless, models that effectively balance both 
characteristics are relatively scarce, particularly in the context of large, heterogeneous multi-omics 
data integration. Furthermore, the integration of omics data types including RNA-Seq, miRNA, and 
DNA methylation is still challenging because most approaches do not capture the intricacies of the 
relationship between the data types. Consequently, there is a growing demand to develop novel 
approaches that are capable of unifying multi-omics data in interpretable and computationally 
efficient frameworks, and with a high prediction power. 
3. Materials and Methods 
3.1 Data Collection 
The multi-omics data for the different cancers used in this study were downloaded from the Pan-
Cancer Atlas [40] using the GDC query tool from the TCGAbiolinks library [41]. The Genomic Data 
Commons is a project set up by the National Cancer Institute which is dedicated to providing a 
central database that can be used by researchers wishing to carry out cancer genomic studies. 
The GDCquery function requires several parameters: project, legacy, data.category, data.type, and 
sample.type. The project parameter determines the TCGA project from which data should be 
retrieved. The TCGA consists of multiple cancer research initiatives, each focusing on a specific 
subtype or aspect of cancer. For this study, the project parameter was set to "TCGA-*", 
encompassing all 33 TCGA projects (cancer types in addition to the normal tissues). The legacy 
parameter was set to True, indicating that the query should retrieve original, unaltered data from the 
TCGA Data Portal's legacy repository. The data.category parameter identifies the relevant category 
for the project, which in this case included transcriptome profiling for mRNA or RNA-Seq, miRNA 
datasets, and the DNA Methylation category for methylation data. The data.type argument was used 
to filter files, specifying Gene Expression Quantification for mRNA or RNA-Seq data, miRNA 
Expression Quantification for miRNA data, and Methylation Beta Value for DNA Methylation data. 
The sample.type parameter defined the sample types to be downloaded; in our case, this was set to 
8 
 
"Primary Solid Tumor" and "Solid Tissue Normal" to extract omics data from both tumor and non-
tumor samples. 
The data was arranged so that the attributes of each data type were listed along the vertical axis, or 
â€˜rowsâ€™, whilst the samples or cases were identified along the horizontal axis, or â€˜columnsâ€™. The tumor 
types and the number of samples included in the TCGA multi-omics data (mRNA, miRNA, and DNA 
methylation) included in this study are depicted in Figure 1. 
Figure 1. Tumor types including the number of samples and normal tissues of TCGA Multi-omics data (mRNA, miRNA, and DNA 
methylation) used in the analysis. 
3.2 Data Preprocessing 
The aim of this study is classification of 31 types of cancer employing RNA-Seq, miRNA, and DNA 
methylation [41]. We normalized the RNA-Seq data and conducted differential gene expression 
(DGE) analysis. The significant genes were selected based on the adjusted p-value for which we set 
the threshold to 0.05 [42]. For miRNA and DNA methylation data, the limma R package was used to 
identify significant features with the cut-off of adjusted p-value set to 0.05 [43]. LASSO regression 
9 
 
was used afterward to further reduce the number of features where those with non-zero coefficients 
were retained [44]. 
3.2.1 Differential Gene Expression (DGE) Analysis  
Differential gene expression (DGE) profiling is a method widely used in genomics to compare the 
levels of gene expression in a given organism under different conditions or environments, for 
example, treatment versus control, or normal versus cancer, etc. [45]. This helps in the 
understanding how genes are regulated and their actions depending on the environmental 
conditions, and a host of other functions. In our analysis for the current study, we performed 
differential gene expression on the mRNA data using the DESeq2 R package. This method takes a 
general linear model of the count data for every gene, using negative binomial distribution to capture 
both biological variation and overdispersion. The values of the estimated log fold changes were 
tested for their significance by the Wald test and the genes were called differentially expressed 
based on the p-values obtained from the Wald statistic. For the purpose of pinpointing genes that 
are likely to be implicated in the biological processes being studied, we set the p-value threshold to 
0.001. 
3.2.2 LIMMA Model 
We applied the LIMMA (Linear Models for Microarray) package to perform the differential methylation 
analysis for which we fit a linear model for the methylation levels of CpG sites as a function of the 
experimental sample groups [46]. The dataset has 9,171 samples and 485,577 features obtained 
from the Human Methylation 450K (HM450) array [47]. Using the LIMMA package, we selected CpG 
sites significantly methylated in tumors compared to normal samples. LIMMA provides a moderated 
t-statistic for each CpG site and provides an estimate of the effect size that reflects the relative 
difference in methylation between the groups. The p-value that corresponds to the t-statistic shows 
the statistical significance of these differences. In this paper, we used a cutoff p-value less than 0.05 
to filter the data, and thus the number of features was reduced to 13,9321 that concentrate on the 
most significant methylation change. 
3.2.3 LASSO Regression Model 
Lasso regression is a linear regression method with an additional term in the objective function by 
which the coefficients of the less important features are reduced to zero. The objective function for 
Lasso regression is defined as: 
10 
 
min
ğ›½{
1
2ğ‘›âˆ‘
(ğ’´ğ‘–âˆ’Î§ğ‘–ğ›½)
2
ğ‘›
ğ‘–=1
+ ğœ†âˆ‘
|ğ›½ğ‘—|
ğ‘
ğ‘—=1
}                                                      (1) 
where the residual sum of squares is 
1
2ğ‘›âˆ‘
(ğ’´ğ‘–âˆ’Î§ğ‘–ğ›½)
2
ğ‘›
ğ‘–=1
, and the L1 penalty term that encourages the 
model to learn sparse coefficients is ğœ†âˆ‘
|ğ›½ğ‘—|
ğ‘
ğ‘—=1
. When adjusted by the parameter ğœ†, Lasso regression 
establishes a reasonable and balanced relationship between the fit and the complexity of the model, 
using the estimates of the coefficients for the most significant features for the prediction of the 
response variable. This approach allows to obtain the final set of features to be used for further 
analysis that exclude less important features. 
For mRNA and DNA methylation data we used the LASSO regression for feature selection and feature 
regularization. After applying LASSO regression, the number of mRNA features decreased from 
26,768 to only 520, and the number of DNA methylation features from 139,321 to 393. The pipeline 
for data processing is summarized in Table 1. 
Table 1. Pipeline for data processing. Row 1 (Original Features): number of original features, Row 2 (Differentially Expressed Genes): 
number of features after applying Differentially Expressed Analysis, Row 3 (LIMMA model): number of features after applying LIMMA 
model, Row 4 (LASSO Regression Model): number of features after applying LASSO Regression Model, Row 5 (All Tumor Samples and 
Normal): number of tumor samples and normal samples, Row 6 (Unique Tumor Samples and Normal): number of tumor and normal 
samples after removing duplicates, Row 7 (Common Samples and Features): number of tumor and normal samples and features common 
across all datatypes, and Row 8 (Network Nodes and Edges): number of nodes and edges for the PPI network for each datatype. 
Datatype 
mRNA 
miRNA 
DNA Methylation 
Original Features 
60,660 
1881 
485,577 
Differentially Expressed Analysis 
26,768 
- 
- 
LIMMA Model (Selected Features) 
- 
- 
139,321 
LASSO Regression Model (Selected Features) 
520 
- 
393 
All Tumor Samples and Normal Tissues 
10,668 
10,465 
9,171 
Unique Tumor Samples and Normal Tissues 
10,667 
10,465 
8,674 
Common Samples and Features 
8,464 Samples and 2,794 Features 
Network Nodes and Edges 
 
504 Nodes and 343 Edges 
 
 
3.3 Multi-Omics Data Integration 
We merged all omics data pertaining to each sample into a single record, integrating mRNA or RNA-
Seq, miRNA, and DNA methylation data using the sample ID as a common value. The inner join 
merging operation was used on the sample ID of the three datasets and only samples with the 
complete data in all the three omics data were retained. This approach helped to address the 
problems of missing data, as the final integrated dataset contains only samples with complete data 
in all three omics datasets. For some cancer types, there were missing data for one or more omics 
data; for instance, â€˜TCGA_LAMLâ€™ cancer type had no RNA-Seq data, and â€˜TCGA_GBMâ€™ had no miRNA 
11 
 
data. For further analysis, we omitted cancer types for which omics data was incompletely 
represented. The final dataset comprises 8,464 samples involving 2,794 omics features and covers 
31 types besides the normal tissues. This dataset is therefore suitable for additional analyses with a 
view of establishing diverse molecular mechanisms that can be associated with various forms of 
cancer. The preprocessing steps and data integration are illustrated in Figure 2. 
 
Figure 2. Preprocessing steps and data integration: First, omics data (mRNA, miRNA, and DNA methylation) were obtained from the Pan-
cancer Atlas using the TCGAbiolinks library. Next, differential expression analysis (DEG) and LASSO regression were applied to mRNA 
data, while LIMMA and LASSO regression were applied to DNA methylation data. Subsequently, mRNA or RNA-Seq, miRNA, and DNA 
methylation data were integrated based on the sample ID using an inner join operation. 
3.4 Graph Structures 
3.4.1 Correlation Matrices 
For the graph construction, we employed two types of graph structures: correlation matrices and the 
molecular topology of PPI networks. The correlation matrix for each omics data type was computed 
to define the graph structure using the correlation coefficient to measure the relationship between 
pairs of features. This correlation matrix to define the graph structure was obtained by taking a cutoff 
at 0.7. The correlation coefficient between pairs of features is as follows: 
ğ‘ğ‘œğ‘Ÿğ‘Ÿ(Î§ğ‘–, Î§ğ‘—) =
ğ‘ğ‘œğ‘£(Î§ğ‘–,Î§ğ‘—)
ğœÎ§ğ‘–ğœÎ§ğ‘—
                                                                       (2) 
12 
 
3.4.2 Protein-Protein Interaction (PPI) Network 
The protein-protein interaction (PPI) network depicts the relationship existing between proteins in a 
cell [48,49]. Proteins interact to conduct numerous biological processes including metabolism, 
gene regulation, and signaling, and therefore PPI networks are crucial for describing 
pathophysiological processes like cancer, and other commonplace cellular processes [50, 51]. The 
PPI network was constructed based on the corresponding genes from the STRING database. The 
String database is a valuable resource for both predicted and experimentally validated PPI data [52]. 
In PPI, the nodes refer to proteins and edges refer to the known relationships between them [48]. 
This data involves the identification of the proteins involved as well as the strength of the interaction 
between them. The nodes and edges were coded as tensors, and afterward were fed into the 
different Graph Network architectures as a part of the structure of the graph. In this graph-based 
representation, each patient is described by the topology of the PPI network incorporating nodes 
with multi-omics features obtained from DNA methylation, miRNA, and mRNA. While the topology 
is identical across the patients, the node features may be different indicating the unique molecular 
profiles of cancer for the specific patient. This approach allows for elaborate and personalized 
assessment of cancer-related molecular signaling. 
3.5 Graph Neural Network Architectures 
3.5.1 Graph Convolutional Networks (GCNs) 
The family of the GCNs generalizes the concept of convolution common for traditional grid data to 
graph data. In GCNs, a node aggregates information from its neighboring nodes to compute its 
features, and thus the model captures the localized spatial structure of a graph. This is especially 
helpful for node classification, graph classification, and link prediction. For instance, GCNs may 
study the protein-protein relations or merge various types of omics data for cancer typing or the 
evolution of a disease. The analysis of the features of GCNs reveals that for the tasks in which the 
graph structure presents a high level of relevance, the algorithms can capture interactions and 
dependencies, which provides high flexibility in the use of ML algorithms and data analysis. The 
layer-wise propagation rule for the GCNs using the correlation matrix or the PPI structure can be 
defined as [12]: 
ğ»(ğ‘™+1) = ğœ(ğ·âˆ’1
2 ğ´ğ·âˆ’1
2 ğ»(ğ‘™)ğ‘Š(ğ‘™))                                                                 (3) 
ğ»(ğ‘™)  stands for the feature matrix at layer l, ğ‘Š(ğ‘™) is a weight matrix, A is an adjacency matrix, ğ· is the 
degree matrix, and ğœ is an activation function [14]. 
13 
 
3.5.2 Graph Attention Networks (GATs) 
GATs are neural network architectures that are capable of learning data representations that are 
arranged in the form of graphs by applying an attention mechanism to the nodes of the graph. While 
GCNs operate by taking an average of all features from the neighboring nodes, GATs also include 
information from neighbors, where using an attention layer permits the model to decide the 
weighting of the parameters based on neighboring nodes. This is accomplished through weighting of 
the graph edges where during the updating of the features of a node, the model pays special 
attention to the most relevant neighbors. GATs are particularly suitable for node classification, graph 
classification, and link prediction problems if the connections between nodes are not all similar and 
all relations are not equally significant. GATs are broadly in bioinformatics, where dense networks 
like protein-protein interactions enhance the predictions in cases like cancer classification. The 
capacity to decide dynamically the contribution of each neighbor makes GATs an effective model for 
learning relatively expressive patterns from graph-based data. The employed attention mechanism 
for the feature update rule of a node is given as follows [53]: 
â„ğ‘–= ğœ(âˆ‘
ğ›¼ğ‘–ğ‘—
ğ‘—âˆˆğ’©(ğ‘–)
ğ‘Šâ„ğ‘—)                                                                        (4) 
and the attention coefficients ğ›¼ğ‘–ğ‘—  are computed using the formula [15]: 
ğ›¼ğ‘–ğ‘—=
exp (ğ¿ğ‘’ğ‘ğ‘˜ğ‘¦ğ‘…ğ‘’ğ¿ğ‘ˆ(ğ‘ğ‘‡[ğ‘Šâ„ğ‘–âˆ¥ğ‘Šâ„ğ‘—]))
âˆ‘
exp (ğ¿ğ‘’ğ‘ğ‘˜ğ‘¦ğ‘…ğ‘’ğ¿ğ‘ˆ(ğ‘ğ‘‡[ğ‘Šâ„ğ‘–âˆ¥ğ‘Šâ„ğ‘˜]))
ğ‘˜âˆˆğ’©(ğ‘–)
                                                           (5) 
3.5.3 Graph Transformer Networks (GTNs) 
GTNs are one of the state-of-the-art neural networks to process graph-structure data. Utilizing the 
attention mechanisms of Transformers, they can learn long-range dependencies, as well as 
embedded interactions inside the graph. In contrast to the original GNNs that use only local 
neighborhood aggregation, GTNs are able to represent more complex relations since the model 
learns which nodes of the graph should attend to each other regardless of their distance in the graph. 
GTNs are effective for node classification, graph classification, and link prediction, since the 
relationships between nodes are more intricate and non-local engagement is more important. In 
bioinformatics, GTNs have been used for the analysis of multi-omics data in which they are capable 
of finding out important patterns and relationships between various levels of biological information 
consisting of transcriptions, methylations, and proteins and their interactions. As a result, GTNs 
offer an alternative methodology for graph processing while retaining both local and global 
14 
 
dependencies inherent in graph-structured data. The update rule for the transformer layer in GTNs 
is as follows [54]: 
ğ»(ğ‘™+1) = ğ‘‡ğ‘Ÿğ‘ğ‘›ğ‘ ğ‘“ğ‘œğ‘Ÿğ‘šğ‘’ğ‘Ÿğ¿ğ‘ğ‘¦ğ‘’ğ‘Ÿ(ğ»(ğ‘™), ğ´)                                                        (6) 
where incorporating self-attention mechanisms [14] described by: 
ğ´ğ‘¡ğ‘¡ğ‘’ğ‘›ğ‘¡ğ‘–ğ‘œğ‘›(ğ‘„, ğ¾, ğ‘‰) = ğ‘ ğ‘œğ‘“ğ‘¡ğ‘šğ‘ğ‘¥(
ğ‘„ğ¾ğ‘‡
âˆšğ‘‘ğ‘˜) ğ‘‰                                                       (7) 
4. Experimental Evaluation 
4.1 Experimental setup 
In this study, the multi-omics data was standardized, and two separate graph structures were 
employed: one based on PPI network and another on gene correlation. The PPI network was 
formulated based on interaction data derived from the String database which shows proteins as 
nodes and their interactions as edges. Each of the graphs was converted to tensors and the multi-
omics data were combined with the nodes of the graph to create data objects that can be fed into 
the graph architecture network independently. This allows comparing the efficiency of each graph 
structure in identifying the molecular connections and dependencies in the data. The model 
architectures of GAT, GTN, and GCN were evaluated with a 5-fold cross-validation approach. 
The GAT architecture consists of four GATConv layers, which were configured with the following 
parameters: the first layer has 1024 output channels and 8 attention heads. The second layer cuts 
down the dimensions to 512 channels and has 4 attention heads. The third layer has 256 channels 
and two attention heads, and the final layer has 32 channels with one attention head. Batch 
Normalization and Leaky ReLU activation are used after each layer. We used 0.5 dropout rate to 
prevent overfitting. We used the Adam optimizer with an initial learning rate of 0.001. A learning rate 
scheduler (ReduceLROnPlateau) is used to adjust the learning rate dynamically based on the 
validation accuracy. Negative Log Likelihood Loss, i.e., cross-entropy, is used as a loss function. The 
model was trained for 100 epochs within each fold of the 5-fold cross-validation, where data was 
split into training and testing sets. The parameters were optimized based on the grid search 
approach. 
The GCN model was designed with the following key parameters where the standardized features 
from multi-omics data are used as an input layer. The model architecture construction starts with 
15 
 
the first GraphConv layer to which the input features are passed in and then proceeds with 2 hidden 
GraphConv layers. Each of the hidden layers has 128 hidden units with ReLU activation function. 
Also, a dropout layer with a 0.5 dropout rate is applied after each layer. The Adam optimizer with a 
learning rate of 0.001 is employed in the training process of 100 epochs. The parameters were 
optimized based on the grid search approach. 
Figure 3. The architecture of the GCN, GAT, and GTN models for multiclass cancer classification. 
The GTN architecture comprises two TransformerConv layers configured with 8 attention heads 
each. The first TransformerConv layer takes the multi-omics data as the input and produces 64 
channels as the output. The second TransformerConv layer additionally processes the output of the 
first TransformerConv layer and reduces the dimensionality to match the number of classes for final 
classification. Each TransformerConv layer is responsible for different portions of the input features 
and also collects data from adjacent nodes in the graph. We used the Adam optimizer with a learning 
rate of 0.001 in the training process. We used the CrossEntropyLoss as a loss function. 
ReduceLROnPlateau was used as a learning rate scheduler to adjust the learning rate based on the 
validation accuracy dynamically. We trained the model for 100 epochs.  
16 
 
4.2 Performances Metrics 
All the models were coded in Python using the PyTorch Geometric library. The multi-omics dataset 
was split into training, validation, and test sets, and the performance of the models was assessed 
using a five-fold cross-validation approach. The evaluation metrics include accuracy, precision, 
recall, and F1-score. The accuracy is: 
ğ´ğ‘ğ‘ğ‘¢ğ‘Ÿğ‘ğ‘ğ‘¦=
ğ‘‡ğ‘ƒ+ğ‘‡ğ‘
ğ‘‡ğ‘ƒ+ğ‘‡ğ‘+ğ¹ğ‘ƒ+ğ¹ğ‘                                                                         (8) 
Since it is a multi-class classification problem, we calculate the macro-averaged precision, recall, 
and F1 score for the folds. The equations are as follows: 
Macro âˆ’Precision =
1
ğ¶âˆ‘
ğ‘‡ğ‘ƒğ‘
ğ‘‡ğ‘ƒğ‘+ğ¹ğ‘ƒğ‘
ğ¶
ğ‘=1
                                                         (9) 
 
Macro âˆ’Recall =
1
ğ¶âˆ‘
ğ‘‡ğ‘ƒğ‘
ğ‘‡ğ‘ƒğ‘+ğ¹ğ‘ğ‘
ğ¶
ğ‘=1
                                                          (10) 
 
Macro âˆ’F1 =
1
ğ¶âˆ‘
2Ã—ğ‘ƒğ‘Ÿğ‘’ğ‘ğ‘–ğ‘ ğ‘–ğ‘œğ‘›ğ‘Ã—ğ‘…ğ‘’ğ‘ğ‘ğ‘™ğ‘™ğ‘
ğ‘ƒğ‘Ÿğ‘’ğ‘ğ‘–ğ‘ ğ‘–ğ‘œğ‘›ğ‘+ğ‘…ğ‘’ğ‘ğ‘ğ‘™ğ‘™ğ‘
ğ¶
ğ‘=1
                                                  (11) 
4.3 Experimental Results 
The performance of the LASSO-MOGCN model for different combinations of multi-omics data when 
the correlation is used as a graph structure is presented in Table 3. The table shows that LASSO-
MOGCN achieved the highest performance when applied to the combination of mRNA or RNA-Seq, 
miRNA, and DNA methylation. In this combination, it achieved an accuracy, precision, recall, and F1 
score of 95.39%Â±0.003, 0.9462Â±0.010, 0.9374Â±0.006, and 0.9380Â±0.004, respectively. This 
indicates that the combination of the three omics data types is able to capture the most 
comprehensive biological signal. The low values of standard deviation imply stable performance 
across different test sets. Generally, the model performance on the combination of multi-omics data 
is better than its performance on single omics data, where the worst performance is achieved when 
it is applied to the miRNA data alone. 
Table 3. Performance metrics of the proposed LASSO-MOGCN approach based on correlation matrices. 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
93.44% Â± 0.005 
0.9197 Â± 0.004 
0.9119 Â± 0.007 
0.9129 Â± 0.003 
17 
 
 
Table 4 shows the performance of LASSO-MOGCN on different combinations of omics data where 
the used graph structure is the PPI network. The best performance is achieved on the omics 
combination of mRNA or RNA-Seq, miRNA, and DNA methylation, where the accuracy, precision, 
recall, and F1 score are 95.10%Â±0.005, 0.9348Â±0.012, 0.9227Â±0.011, and 0.9250Â±0.011, 
respectively. This performance is lower than that achieved when the correlation is used as a graph 
structure, presented in Table 3. The results suggest that although the PPI network affords unique 
insight into the protein interactions, it may not capture the necessary interdependencies of the 
multi-omics characteristics as correlation matrices. 
Table 4. Performance metrics of the proposed LASSO-MOGCN approach based on PPI Network. 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
87.92% Â± 0.004 
0.8611 Â± 0.015 
0.8500 Â± 0.015 
0.8521 Â± 0.015 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
91.70% Â± 0.008 
0.8838 Â± 0.027 
0.8663 Â± 0.021 
0.8657 Â± 0.023 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
94.05% Â± 0.003 
0.9331 Â± 0.008 
0.9204 Â± 0.013 
0.9224 Â± 0.011 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.30% Â± 0.004 
0.9392 Â± 0.009 
0.9309 Â± 0.005 
0.9320 Â± 0.003 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
93.96% Â± 0.002 
0.9255 Â± 0.019 
0.9109 Â± 0.008 
0.9147 Â± 0.012 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.39% Â± 0.003 
0.9462 Â± 0.010 
0.9374 Â± 0.006 
0.9380 Â± 0.004 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
93.36% Â± 0.002 
0.9175 Â± 0.003 
0.9049 Â± 0.013 
0.9059 Â± 0.006 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
88.26% Â± 0.003 
0.8572 Â± 0.015 
0.8424 Â± 0.007 
0.8446 Â± 0.009 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.23% Â± 0.002 
0.9205 Â± 0.017 
0.9116 Â± 0.015 
 0.9129 Â± 0.015 
18 
 
 
Table 5 presents the results of applying LASSO-MOGAT to classify the 31 types of cancers in addition 
to the normal tissues based on a combination of multi-omics data and the correlation matrix as a 
graph structure. The model achieved the highest accuracy (94.88%) among the single omics data 
when using DNA methylation alone. However, the model achieved better performances when the 
DNA methylation is combined with other omics data, E.g., the combination of mRNA/RNA-Seq and 
DNA methylation shows an accuracy of 95.67%, as well this combination shows robust precision, 
recall, and F1 scores. The best performance is achieved when the three omics data are integrated, 
where the accuracy, precision, recall, and F1 scores of the model are 95.90%Â±0.001, 0.9438 Â±0.008, 
0.9445Â±0.009, and 0.9420Â±0.008, respectively. 
Table 5. Performance metrics of the proposed LASSO-MOGAT approach based on correlation matrices. 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
93.98% Â± 0.001 
0.9275 Â± 0.017 
0.9197 Â± 0.011 
0.9201 Â± 0.013 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.35% Â± 0.004 
0.9445 Â± 0.011 
0.9291 Â± 0.009 
0.9328 Â± 0.011 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
93.72% Â± 0.006 
0.9170 Â± 0.019 
0.9024 Â± 0.018 
0.9058 Â± 0.018 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.10% Â± 0.005 
0.9348 Â± 0.012 
0.9227 Â± 0.011 
0.9250 Â± 0.011 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
93.88% Â± 0.004 
0.9169 Â± 0.006 
0.9283 Â± 0.013  
0.9205 Â± 0.006 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
89.59% Â± 0.007 
0.8665 Â± 0.009 
0.8636 Â± 0.011 
0. 8613 Â± 0.006 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.88% Â± 0.003 
0.9226 Â±0.011 
0.9294 Â± 0.013 
0.9242 Â± 0.011 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
94.55% Â± 0.004 
0.9229 Â± 0.014 
0.9258 Â± 0.008 
0.9224 Â± 0.011 
19 
 
 
Table 6 presents the performance of the LASSO-MOGAT technique for classifying 31 types of cancer 
and normal tissues based on a PPI network. Even though single omics data types like DNA 
methylation or mRNA yield high accuracy, the results are significantly enhanced when the omics 
data types are combined. This combination yields the best results with an accuracy of 95.74%, and 
precision, recall, and F1 scores all above 93%. 
Table 6. Performance metrics of the proposed LASSO-MOGAT approach based on PPI Network. 
 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.67% Â± 0.002 
0.9316 Â± 0.012 
0.9375 Â± 0.017 
0.9331 Â± 0.015 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.81% Â± 0.005 
0.9202 Â± 0.010 
0.9248 Â± 0.007 
0.9189 Â± 0.009 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.90% Â± 0.001 
0.9438 Â± 0.008 
0.9445 Â± 0.009 
0.9420 Â± 0.008 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
93.67% Â± 0.004 
0.9175 Â± 0.007 
0.9185 Â± 0.013 
0.9149 Â± 0.010 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
89.15% Â± 0.003 
0.8512 Â± 0.007 
0.8513 Â± 0.007 
0.8482 Â± 0.007 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.61% Â± 0.003 
0.9185 Â± 0.016 
0.9188 Â± 0.017 
0.9170 Â± 0.016  
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
94.11% Â± 0.007 
0.9160 Â± 0.023 
0.9158 Â± 0.014 
0.9128 Â± 0.015 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.53% Â± 0.002 
0.9395 Â± 0.004 
0.9428 Â± 0.007 
0.9399 Â± 0.006 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.80% Â± 0.007 
0.9134 Â± 0.023 
0.9154 Â± 0.019 
0.9126 Â± 0.021 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.74% Â± 0.003 
0.9450 Â± 0.009 
0.9354 Â± 0.011 
0.9362 Â± 0.011 
20 
 
Table 7 shows the performance of LASSO-MOGTN for classifying 31 cancer types in addition to the 
normal tissues.  LASSO-MOGTN approach based on correlation matrix yields good performance 
when mRNA or RNA-Seq and DNA methylation data information is used. Notably, when using all 
three omics types the accuracy remains moderate and equals 94%. It is important to note that 
LASSO-MOGTN has good performance when combining mRNA or RNA-Seq with other omics data 
types, such as miRNA and DNA methylation. Therefore, mRNA or RNA-Seq data might be more 
beneficial for cancer classification using LASSO-MOGTN with the correlation matrix-based 
approach. LASSO-MOGTN might fail to take full advantage of the synergistic potential of multiple 
omics data. 
Table 7. Performance metrics of the proposed LASSO-MOGTN approach based on correlation matrices. 
 
The evaluation results for the LASSO-MOGTN using the PPI network for classifying 31 types of cancer 
and the normal tissues are displayed in Table 8. When using mRNA or RNA-Seq data alone, the model 
achieved accuracy and F1-Score of 93.37% and 0.9043 respectively. The highest performance is 
achieved when combining mRNA with DNA methylation, where the accuracy, precision, recall, and 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
92.53% Â± 0.002 
0.9051 Â± 0.013 
0.9014 Â± 0.012 
0.9007 Â± 0.012 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
84.78% Â± 0.006 
0.8267 Â± 0.021 
0.8018 Â± 0.009 
0.8088 Â± 0.015 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
93.43% Â± 0.006 
0.9178 Â± 0.019 
0.9017 Â± 0.022 
0.9035 Â± 0.021 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
92.46% Â± 0.006 
0.9116 Â± 0.018 
0.8989 Â± 0.015 
0.9027 Â± 0.017 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.01% Â± 0.002 
0.9419 Â± 0.010 
0.9319 Â± 0.009 
0.9347 Â± 0.009 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
92.72% Â± 0.006 
0.9152 Â± 0.010 
0.8991 Â± 0.011 
0.9044 Â± 0.009 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.06% Â± 0.007 
0.9204 Â± 0.026 
0.9089 Â± 0.024 
0.9101 Â± 0.023 
21 
 
F1 score were 95.29%Â±0.002, 0.9412Â±0.005, 0.9351Â±0.005, and 0.9361Â±0.005, respectively. The 
integration of the three omics types yielded an accuracy, precision, recall, and F1 score of 
95.25%Â±0.004, 0.9386Â±0.020, 0.9302Â±0.015, and 0.9318Â±0.018. This integration further highlights 
the benefits of integrating several omics data in the GTN model based on the PPI network. 
Table 8. Performance metrics of the proposed LASSO-MOGTN approach based on PPI Network. 
5. Discussion 
This study provides an empirical analysis of the performance of different graph-based architectures 
for classifying 31 different types of cancer in addition to normal tissues. The architectures LASSO-
MOGCN, LASSO-MOGAT, and LASSO-MOGTN were built based on the two-graph structures, 
correlation matrices and PPI network. Different feature combinations from multi-omics data 
comprising DNA methylation, miRNA, and mRNA or RNA-Seq are employed. The LASSO-MOGCN 
model shows the best performance when using the features combination mRNA or RNA-Seq, 
miRNA, and DNA methylation based on the correlation matrix as graph structure. The accuracy, 
precision, recall, and F1-score obtained based on this model were 95.39%Â±0.003, 0.9462Â±0.010, 
Data Types 
Multi-Omics Data Type 
Cancer Types 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Single Omics 
Data 
mRNA or RNA-Seq 
31 Types of 
Cancer and 
Normal Tissues 
93.37% Â± 0.005 
0.9153 Â± 0.006 
0.9040 Â± 0.013 
0.9043 Â± 0.010 
Single Omics 
Data 
miRNA 
31 Types of 
Cancer and 
Normal Tissues 
88.58% Â± 0.003 
0.8666 Â± 0.008 
0.8519 Â± 0.012 
0.8560 Â± 0.009 
Single Omics 
Data 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.38% Â± 0.001 
0.9253 Â± 0.014 
0.9151 Â± 0.008 
0.9182 Â± 0.010 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and miRNA 
31 Types of 
Cancer and 
Normal Tissues 
93.97% Â± 0.003 
0.9338 Â± 0.009 
0.9225 Â± 0.010 
0.9231 Â± 0.011 
Multi-Omics 
Data 
mRNA or RNA-Seq 
and DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.29% Â± 0.002 
0.9412 Â± 0.005 
0.9351 Â± 0.005 
0.9361 Â± 0.005 
Multi-Omics 
Data 
miRNA and DNA 
methylation 
31 Types of 
Cancer and 
Normal Tissues 
94.37% Â± 0.005 
0.9323 Â± 0.021 
0.9177 Â± 0.016 
0.9210 Â± 0.018 
Multi-Omics 
Data 
mRNA or RNA-Seq, 
miRNA and 
DNA methylation 
31 Types of 
Cancer and 
Normal Tissues 
95.25% Â± 0.004 
0.9386 Â± 0.020 
0.9302 Â± 0.015 
0.9318 Â± 0.018 
22 
 
0.9374Â±0.006, and 0.9380Â±0.004 respectively. This suggests that the GCN method can perform very 
well compared to other graph-based architectures with multi-omics data in classifying the cancer 
types when it uses correlation matrices as a graph structure. On the other hand, LASSO-MOGCN 
based on PPI network shows a performance lower than when it uses the correlation matrix and it 
obtained an accuracy, precision, recall, and F1-score of 95.10%Â±0.005, 0.9348Â±0.012, 
0.9227Â±0.011, and 0.9250Â±0.011 respectively. The performance suggests that LASSO-MOGCN 
performs well and this discrepancy most likely results from the GCN structure's utilization of the 
data correlations. 
LASSO-MOGTN based on the correlation matrix shows a lower performance compared to LASSO-
MOGCN where it obtained an accuracy, precision, recall, and F1 Score of 94.06%Â±0.007, 
0.9204Â±0.026, 0.9089Â±0.024, and 0.9101Â±0.023, respectively. Unlike LASSO-MOGCN, LASSO-
MOGTN obtained better performance with the PPI network, resulting in accuracy, precision, recall, 
and F1 Score of 95.25%Â±0.004, 0.9386Â±0.020, 0.9302Â±0.015, and 0.9318Â±0.018, respectively. 
Because of its structure or the unique characteristics of the data, the GTN model may not have been 
able to fully utilize the potential of correlation matrices, and it is more suited to leveraging the 
interactions captured in PPI networks. 
LASSO-MOGAT has the best performance compared to the other models when using either the PPI 
network or the correlation matrix. Based on the PPI network, LASSO-MOGAT achieved an accuracy, 
precision, recall, and F1-score of 95.74%Â±0.003, 0.9450Â±0.009, 0.9354Â±0.011, and 0.9362Â±0.011, 
respectively. This is the best performance compared to the other models when using the PPI 
network. The performance for correlation matrices of LASSO-MOGAT includes accuracy, precision, 
recall, and F1-score of 95.90%Â±0.001, 0.9438Â±0.008, 0.9445Â±0.009, and 0.9420Â±0.008.   
This study reaffirms the efficacy of the GAT approach with correlation matrices for multi-omics data 
and with the PPI networks for comprehending intricate cellular interactions. Selecting the framework 
and data structure proves to be influential to the classification process. 
Figure 4 shows the ROC curves for cancer types of classification using LASSO-MOGAT. The AUC of 
the classes TCGA-BLCA, TCGA-BRCA, and TCGA-ESCA reach an AUC of 1. It can also be noted that 
most of the ROC curves tend to be closer to the top left-hand corner indicating a high true positive 
rate and low false positive rate. Only two classes, TCGA-CHOL and TCGA-READ, show slightly lower 
AUC of 0. 97 and 0. 95, respectively, meaning that our approach can classify these types with less 
23 
 
accuracy. The high AUC score obtained in all classes indicates that the proposed model is capable 
of differentiating between different cancer types well. 
 
Figure 4. ROC Curves and AUC Scores for Multi-Omics Cancer Classification Using GAT Model Across TCGA Cancer Types. 
Figure 5 shows the performance comparison of different models. Four key performance metrics are 
evaluated: accuracy, precision, recall, and F1 score. As depicted in the figure, we observe that the 
best-performing model is LASSO-MOGAT, which archives the highest accuracy (95.9%), recall 
(94.45%), and F1 score. Although LASSO-MOGAT outperforms LASSO-MOGCN in terms of accuracy, 
recall, and F1 score, LASSO-MOGCN gives higher precision which illustrates the modelâ€™s capability 
of predicting the positive instances with higher probability. 
Table 9 presents a comparison of the performance of different models in cancer classification based 
on different multi-omics data. The comparison with other models for breast cancer subtypes as well 
as other cancer classes shows better performance of the proposed LASSO-MOGAT model with an 
accuracy of 95.90% for 32 cancer classes using mRNA, miRNA, and DNA methylation data. The 
models by Mostavi et al. (1D-CNN, 2D-Vanilla-CNN, and 2D- Hybrid-CNN) have slightly lower 
24 
 
accuracy, where 1D-CNN and 2D-Hybrid-CNN models achieve 95.50% and 95.70%, respectively. 
The GCNN-PPI model proposed by Ramirez et al. [22] is trained for PPI networks and mRNA data and 
it is less accurate in comparison with LASSO-MOGAT. Thus, the results show that the inclusion of 
multiple omics data in the LASSO-MOGAT model enhances the classification performance. 
 
Figure 5. Performance comparison of the different models based on multi-omics data types and graph structures. 
Table 9. Performance metrics for related Single-Omics and Multi-Omics graph methods based on PPI Network. 
Authors  
&  
Models 
Classes 
Multi-Omics Data type 
 
 
mRNA 
miRNA 
DNA 
methylation 
Accuracy 
Mean Â± std 
Precision 
Mean Â± std 
Recall 
Mean Â± std 
F1 Score 
Mean Â± std 
Proposed LASSO-
MOGAT 
32 
Classes 
âˆš 
âˆš 
âˆš 
0.9590 Â± 0.001 
0.9438 Â± 0.008 
0.9445 Â± 0.009 
0.9420 Â± 0.008 
Mostavi  
et al., 2020 [55] 
1D-CNN 
34 
Classes 
 
 
âˆš 
 
 
- 
 
 
- 
 
 
0.9550 Â± 0.100 
 
 
- 
 
 
- 
 
 
- 
2D-Vanilla-CNN 
âˆš 
- 
- 
0.9487 Â± 0.040 
- 
- 
- 
2D-Hybrid-CNN 
âˆš 
- 
- 
0.9570 Â± 0.100 
- 
- 
- 
Ramirez  
et al., 2020 [22] 
34 
Classes 
âˆš 
- 
- 
 
 
 
 
 
 
 
 
25 
 
GCNN-PPI graph 
0.8898 Â± 0.883 
0.8775    
0.8379 
- 
GCNN-PPI + 
singleton graph 
âˆš 
- 
- 
0.9461 Â± 0.107 
0.9276 
0.9219 
- 
Kaczmarek  
et al., 2022 [33] 
GTN 
12 
Classes 
âˆš 
âˆš 
- 
0.9356 Â± 0.910 
- 
- 
- 
6. Conclusion 
This study presents a novel approach for integrating multi-omics data using graph-based machine 
learning models, which achieves state-of-the-art performance in classifying 31 cancer types and 
normal tissues. The method employs LASSO regression to select the most significant features and 
leverages graph-based architectures such as GCN, GAT, and GTN to model biological interactions 
within the data. Experimental results demonstrate that the LASSO-MOGAT model based on 
integrating mRNA, miRNA, and DNA methylation data improves cancer classification outcomes and 
achieves the highest accuracy of class separation, as well as balanced precision, recall, and F1 
score. These results highlight the importance of multi-omics data integration for accurate cancer 
classification particularly when combined with correlation matrices structures in GAT models. In 
conclusion, this framework holds promise for improving early cancer diagnosis and advancing 
personalized medicine, and potentially contributing to more effective patient care. 
References: 
1. Gibney, E. R., & Nolan, C. M. (2010). Epigenetics and gene expression. Heredity, 105(1), 4-13. 
2. Khan, O. M., Mallardo, D., & Decock, J. (2024). Cancer genomics in the era of precision medicine. 
Frontiers in Genetics, 15, 1378917. 
3. MenyhÃ¡rt, O., & GyÅ‘rffy, B. (2021). Multi-omics approaches in cancer research with applications in 
tumor subtyping, prognosis, and diagnosis. Computational and structural biotechnology journal, 19, 
949-960. 
4. Kwon, H. J., Park, U. H., Goh, C. J., Park, D., Lim, Y. G., Lee, I. K., ... & Lee, M. S. (2023). Enhancing lung 
cancer classification through integration of liquid biopsy multi-omics data with machine learning 
techniques. Cancers, 15(18), 4556. 
5. Hanczar, B., Bourgeais, V., & Zehraoui, F. (2022). Assessment of deep learning and transfer learning 
for cancer prediction based on gene expression data. BMC bioinformatics, 23(1), 262. 
6. DÃ­az-Uriarte, R., & Alvarez de AndrÃ©s, S. (2006). Gene selection and classification of microarray data 
using random forest. BMC bioinformatics, 7, 1-13. 
7. Mao, X., Peng, L., & Wang, Z. (2022). Nonparametric feature selection by random forests and deep 
neural networks. Computational Statistics & Data Analysis, 170, 107436. 
8. Liu, S., Xu, C., Zhang, Y., Liu, J., Yu, B., Liu, X., & Dehmer, M. (2018). Feature selection of gene 
expression data for cancer classification using double RBF-kernels. BMC bioinformatics, 19, 1-14. 
9. Wekesa, J. S., & Kimwele, M. (2023). A review of multi-omics data integration through deep learning 
approaches for disease diagnosis, prognosis, and treatment. Frontiers in Genetics, 14, 1199087. 
26 
 
10. Park, M. K., Lim, J. M., Jeong, J., Jang, Y., Lee, J. W., Lee, J. C., ... & Kim, K. C. (2022). Deep-learning 
algorithm and concomitant biomarker identification for NSCLC prediction using multi-omics data 
integration. Biomolecules, 12(12), 1839. 
11. Wu, Z., Pan, S., Chen, F., Long, G., Zhang, C., & Philip, S. Y. (2020). A comprehensive survey on graph 
neural networks. IEEE transactions on neural networks and learning systems, 32(1), 4-24. 
12. Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling polypharmacy side effects with graph 
convolutional networks. Bioinformatics, 34(13), i457-i466. 
13. Zhang, X., Zhang, J., Sun, K., Yang, X., Dai, C., & Guo, Y. (2019, November). Integrated multi-omics 
analysis using variational autoencoders: application to pan-cancer classification. In 2019 IEEE 
International Conference on Bioinformatics and Biomedicine (BIBM) (pp. 765-769). IEEE. 
14. Kipf, T. N., & Welling, M. (2016). Semi-supervised classification with graph convolutional 
networks. arXiv preprint arXiv:1609.02907. 
15. VeliÄkoviÄ‡, P., Cucurull, G., Casanova, A., Romero, A., Lio, P., & Bengio, Y. (2017). Graph attention 
networks. arXiv preprint arXiv:1710.10903. 
16. Yun, S., Jeong, M., Kim, R., Kang, J., & Kim, H. J. (2019). Graph transformer networks. Advances in 
neural information processing systems, 32. 
17. Alharbi, F., & Vakanski, A. (2023). Machine learning methods for cancer classification using gene 
expression data: A review. Bioengineering, 10(2), 173. 
18. Valous, N. A., Popp, F., ZÃ¶rnig, I., JÃ¤ger, D., & Charoentong, P. (2024). Graph machine learning for 
integrated multi-omics analysis. British Journal of Cancer, 1-7. 
19. Ryan, B., Marioni, R. E., & Simpson, T. I. (2024). Multi-Omic Graph Diagnosis (MOGDx): A data 
integration tool to perform classification tasks for heterogeneous diseases. Bioinformatics, 40(9), 
btae523. 
20. Ren, Y., Gao, Y., Du, W., Qiao, W., Li, W., Yang, Q., ... & Li, G. (2024). Classifying breast cancer using 
multi-view graph neural network based on multi-omics data. Frontiers in Genetics, 15, 1363896. 
21. Li, B., & Nabavi, S. (2024). A multimodal graph neural network framework for cancer molecular 
subtype classification. BMC bioinformatics, 25(1), 27. 
22. Ramirez, R., Chiu, Y. C., Hererra, A., Mostavi, M., Ramirez, J., Chen, Y., ... & Jin, Y. F. (2020). 
Classification of cancer types using graph convolutional neural networks. Frontiers in physics, 8, 203. 
23. Schulte-Sasse, R., Budach, S., Hnisz, D., & Marsico, A. (2021). Integration of multiomics data with 
graph convolutional networks to identify new cancer genes and their associated molecular 
mechanisms. Nature Machine Intelligence, 3(6), 513-526. 
24. Alharbi, F., Vakanski, A., Elbashir, M. K., & Mohammed, M. (2024). LASSOâ€“MOGAT: a multi-omics 
graph attention framework for cancer classification. Academia Biology, 2(3). 
25. Xiao, S., Lin, H., Wang, C., Wang, S., & Rajapakse, J. C. (2023). Graph neural networks with multiple 
prior knowledge for multi-omics data analysis. IEEE Journal of Biomedical and Health Informatics. 
26. Chatzianastasis, M., Vazirgiannis, M., & Zhang, Z. (2023). Explainable multilayer graph neural network 
for cancer gene prediction. Bioinformatics, 39(11), btad643. 
27. Moon, S., & Lee, H. (2022). MOMA: a multi-task attention learning algorithm for multi-omics data 
interpretation and classification. Bioinformatics, 38(8), 2287-2296. 
28. Li, B.; Wang, T.; Nabavi, S. Cancer Molecular Subtype Classification by Graph Convolutional Networks 
on Multi-Omics Data. In Proceedings of the 12th ACM Conference on Bioinformatics, Computational 
Biology, and Health Informatics, Gainesville, FL, USA, 1â€“4 August 2021. 
29. Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021). MOGONET integrates 
multi-omics data using graph convolutional networks allowing patient classification and biomarker 
identification. Nature communications, 12(1), 3445. 
30. Peng, W., Tang, Q., Dai, W., & Chen, T. (2022). Improving cancer driver gene identification using multi-
task learning on graph convolutional network. Briefings in Bioinformatics, 23(1), bbab432. 
27 
 
31. Zhang, L., Shen, W., Li, P., Xu, C., Liu, D., He, W., ... & Qiao, N. (2021). AutoGGN: a gene graph network 
AutoML tool for multi-omics research. Artificial Intelligence in the Life Sciences, 1, 100019. 
32. Guo, H., Lv, X., Li, Y., & Li, M. (2023). Attention-based GCN integrates multi-omics data for breast 
cancer subtype classification and patient-specific gene marker identification. Briefings in Functional 
Genomics, 22(5), 463-474. 
33. Kaczmarek, E., Jamzad, A., Imtiaz, T., Nanayakkara, J., Renwick, N., & Mousavi, P. (2021). Multi-omic 
graph transformers for cancer classification and interpretation. In PACIFIC SYMPOSIUM ON 
BIOCOMPUTING 2022 (pp. 373-384). 
34. Wang, J., Liao, N., Du, X., Chen, Q., & Wei, B. (2024). A semi-supervised approach for the integration 
of multi-omics data based on transformer multi-head self-attention mechanism and graph 
convolutional networks. BMC genomics, 25(1), 86. 
35. Chai, H., Zhou, X., Zhang, Z., Rao, J., Zhao, H., & Yang, Y. (2021). Integrating multi-omics data through 
deep learning for accurate cancer prognosis prediction. Computers in biology and medicine, 134, 
104481. 
36. Khemani, B., Patil, S., Kotecha, K., & Tanwar, S. (2024). A review of graph neural networks: concepts, 
architectures, techniques, challenges, datasets, applications, and future directions. Journal of Big 
Data, 11(1), 18. 
37. Lachi, D., Azabou, M., Arora, V., & Dyer, E. (2024). GraphFM: A Scalable Framework for Multi-Graph 
Pretraining. arXiv preprint arXiv:2407.11907. 
38. Zhao, X., Liu, H., Dai, Q., Peng, H., Bai, X., & Peng, H. (2023, December). Multi-omics Sampling-based 
Graph Transformer for Synthetic Lethality Prediction. In 2023 IEEE International Conference on 
Bioinformatics and Biomedicine (BIBM) (pp. 785-792). IEEE. 
39. Yang, W., Wu, W., Wang, L., Zhang, S., Zhao, J., & Qiang, Y. (2023). PMSG-Net: A priori-guided 
multilevel graph transformer fusion network for immunotherapy efficacy prediction. Computers in 
Biology and Medicine, 164, 107371. 
40. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellrott, K., ... & Stuart, J. 
M. (2013). The cancer genome atlas pan-cancer analysis project. Nature genetics, 45(10), 1113-1120. 
41. Colaprico, A., Silva, T. C., Olsen, C., Garofano, L., Cava, C., Garolini, D., ... & Noushmehr, H. (2016). 
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic acids 
research, 44(8), e71-e71. 
42. Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. bioinformatics, 26(1), 139-140. 
43. Ritchie, M. E., Phipson, B., Wu, D. I., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma powers 
differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids 
research, 43(7), e47-e47. 
44. Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the Royal Statistical 
Society Series B: Statistical Methodology, 58(1), 267-288. 
45. Rapaport, F., Khanin, R., Liang, Y., Pirun, M., Krek, A., Zumbo, P., ... & Betel, D. (2013). Comprehensive 
evaluation of differential gene expression analysis methods for RNA-seq data. Genome biology, 14, 1-
13. 
46. Chen, J., Long, M. D., Sribenja, S., Ma, S. J., Yan, L., Hu, Q., ... & Yao, S. (2023). An epigenome-wide 
analysis of socioeconomic position and tumor DNA methylation in breast cancer patients. Clinical 
Epigenetics, 15(1), 68. 
47. Pidsley, R., Y Wong, C. C., Volta, M., Lunnon, K., Mill, J., & Schalkwyk, L. C. (2013). A data-driven 
approach to preprocessing Illumina 450K methylation array data. BMC genomics, 14, 1-10. 
48.  Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., ... & Mering, C. V. (2019). 
STRING v11: proteinâ€“protein association networks with increased coverage, supporting functional 
discovery in genome-wide experimental datasets. Nucleic acids research, 47(D1), D607-D613. 
28 
 
49. Zainal-Abidin RA, Afiqah-Aleng N, Abdullah-Zawawi MR, Harun S, Mohamed-Hussein ZA. Protein-
Protein Interaction (PPI) Network of Zebrafish Oestrogen Receptors: A Bioinformatics Workflow. Life 
(Basel). 2022 Apr 27;12(5):650. doi: 10.3390/life12050650. PMID: 35629318; PMCID: PMC9143887. 
50. Morris R, Black KA, Stollar EJ. Uncovering protein function: from classification to complexes. Essays 
Biochem. 2022 Aug 10;66(3):255-285. 
51. Hu, H., Wang, H., Yang, X. et al. Network pharmacology analysis reveals potential targets and 
mechanisms of proton pump inhibitors in breast cancer with diabetes. Sci Rep 13, 7623 (2023).  
52. Damian Szklarczyk, Annika L Gable, Katerina C Nastou, David Lyon, Rebecca Kirsch, Sampo Pyysalo, 
Nadezhda T Doncheva, Marc Legeay, Tao Fang, Peer Bork, Lars J Jensen, Christian von Mering, The 
STRING database in 2021: customizable proteinâ€“protein networks, and functional characterization of 
user-uploaded gene/measurement sets, Nucleic Acids Research, Volume 49, Issue D1, 8 January 
2021, Pages D605â€“D612. 
53. Abu-El-Haija, S., Perozzi, B., Al-Rfou, R., & Alemi, A. A. (2018). Watch your step: Learning node 
embeddings via graph attention. Advances in neural information processing systems, 31. 
54. Wang, X., Ji, H., Shi, C., Wang, B., Ye, Y., Cui, P., & Yu, P. S. (2019, May). Heterogeneous graph attention 
network. In The world wide web conference (pp. 2022-2032). 
55. Mostavi, M., Chiu, Y. C., Huang, Y., & Chen, Y. (2020). Convolutional neural network models for cancer 
type prediction based on gene expression. BMC medical genomics, 13, 1-13. 
